Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma

Whitney B. Pope, A. Lai, R. Mehta, H. J. Kim, J. Qiao, Jonathan R Young, X. Xue, J. Goldin, M. S. Brown, P. L. Nghiemphu, A. Tran, T. F. Cloughesy

Research output: Contribution to journalArticle

123 Scopus citations

Abstract

BACKGROUND AND PURPOSE: Currently it is difficult to predict tumor response to anti-angiogenic therapy in individual patients. Our aim was to determine if ADC histogram analysis can stratify progression-free and overall survival in patients with newly diagnosed GBM treated "up-front" (ie, before tumor recurrence) with bevacizumab. MATERIALS AND METHODS: Up-front bevacizumab-treated and control patients (n = 59 and 62, respectively) with newly diagnosed GBM were analyzed by using an ADC histogram approach based on enhancing tumor. Progression-free and overall survival was determined by using Cox proportional HRs and the Kaplan-Meier method with logrank and Wilcoxon tests. RESULTS: For up-front bevacizumab-treated patients, lower ADCL was associated with significantly longer progression-free survival (median, 459 days for ADCL < 1200 versus 315 days for ADCL ≥ 1200 10-6mm2/s; P = .008, logrank test) and trended with longer overall survival (581 versus 429 days, P = .055). ADC values did not stratify progression-free or overall survival for patients in the control group (P = .92 and P = .22, respectively). Tumors with MGMT promoter methylation had lower ADCL values than unmethylated tumors (mean, 1071 versus 1183 10 -6mm2/s; P = .01, 2-group t test). CONCLUSIONS: Pretreatment ADC histogram analysis can stratify progression-free survival in bevacizumab-treated patients with newly diagnosed GBM. Lower ADC is associated with tumor MGMT promoter methylation, which may, in part, account for the favorable outcome associated with low ADCL tumors.

Original languageEnglish (US)
Pages (from-to)882-889
Number of pages8
JournalAmerican Journal of Neuroradiology
Volume32
Issue number5
DOIs
StatePublished - May 1 2011
Externally publishedYes

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma'. Together they form a unique fingerprint.

  • Cite this

    Pope, W. B., Lai, A., Mehta, R., Kim, H. J., Qiao, J., Young, J. R., Xue, X., Goldin, J., Brown, M. S., Nghiemphu, P. L., Tran, A., & Cloughesy, T. F. (2011). Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma. American Journal of Neuroradiology, 32(5), 882-889. https://doi.org/10.3174/ajnr.A2385